- •This brief report describes characteristics of the first 114 individuals colonized with C. auris identified through active surveillance/screening by NYS Department of Health.
- •“Colonized/screened” individuals were old (median age, 74 years), had extensive health care exposures and underlying conditions (e.g., multiple health care facility admissions and requiring mechanical ventilation), and had 30- and 90-day mortality rates of 17.5% and 37.7%, respectively (although may not be attributable).
- •This description adds to the collective understanding of C. auris in the United States.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to American Journal of Infection Control
Centers for Disease Control and Prevention. Candida auris info for laboratories and health professionals [cited 2021 July 26]. Accessed June 12, 2021. https://www.cdc.gov/fungal/candida-auris/health-professionals.html
- Candida auris in healthcare facilities, New York, USA 2013-2017.Emerg Infect Dis. 2018; 24: 1816-1824
New York State Department of Health. Get the facts about Candida auris [cited 2021 October 24, 2021]. Accessed June 12, 2021. https://www.health.ny.gov/diseases/communicable/c_auris/
- Multiple introductions and subsequent transmission of multidrug-resistant Candida auris, a globally emerging invasive, multidrug-resistant fungus—United State, May 2013-August 2016.Lancet Infect Dis. 2018; 18: 1377-1384
- New York State 2016-2018: Progression from Candida auris Colonization to Bloodstream Infection.Poster at IDWeek, San Francisco2018
Centers for Disease Control and Prevention. National notifiable disease surveillance system, surveillance definition—C. auris. [cited 2021 July 26]. Accessed June 12, 2021. https://ndc.services.cdc.gov/conditions/candida-auris/
- The Value Added From C. auris Point Prevalence and Environmental Studies in NYS.ID Week Poster, 2018
- Development and validation of a real-time PCR assay for rapid detection of Candida auris from surveillance samples.J Clin Microbiol. 2018; 56: E01223
- Factors associated with Candida auris colonization and transmission in skilled nursing facilities with ventilator units, New York, 2016–2018.Clin Infect Dis. 2020; 72: e753-e760
- Repeated point prevalence surveys of Candida auris and carbapenemase producing organisms in a Chicago ventilator-capable skilled nursing facility, Chicago-Illinois, 2018.in: SHEA Spring Meeting 2019; April 24–26, Boston2019
- Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface.J Clin Microbiol. 2017; 55: 2996-3005
Environmental Protection Agency (EPA). LIST P and K: EPA's registered antimicrobial products effective against Clostridium difficile spores. 2019 (cited 2019 July 24). Accessed June 12, 2021. https://www.epa.gov/pesticide-registration/list-p-antimicrobial-products-registered-epa-claims-against-candida-auris and https://www.epa.gov/pesticide-registration/list-k-epas-registered-antimicrobial-products-effective-against-clostridium.
Centers for Disease Control and Prevention. Interim guidance for a public health response to contain novel or targeted multidrug-resistant organisms (MDROs). 2019 (cited 2021 April 10). Accessed June 12, 2021. https://www.cdc.gov/hai/containment/guidelines.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fhai%2Foutbreaks%2Fmdro%2Findex.html
- Candida auris outbreak in a COVID-19 specialty care unit—Florida, July–August 2020.MMWR. 2021; 70: 56-57
- Genomic characterizations of clade III lineage of Candida auris, California, USA.EID. 2021; 27: 1223-1227
Funding/support: This work was supported by Cooperative Agreement Number CK000423-01S2, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services or the New York State Department of Health.
Previous presentation: A preliminary version of the work was presented as an oral abstract to APIC 2019 Annual Meeting, Philadelphia, PA.
Conflicts of interest: None to report